Serum Inflammation Biomarkers and Micronutrient Levels in Nigerian Breast Cancer Patients with Different Hormonal Immunohistochemistry Status

Main Article Content

Ganiyu Olatunbosun Arinola
Fabian Victory Edem
Abayomi Benjamin Odetunde
Christopher Olusola Olopade
Olufunmilayo Ibironke Olopade

Keywords

Cytokines, Breast cancer, Inflammation, Methylation , Micronutrients

Abstract

Background: The importance and relevance of serum inflammation biomarkers and DNA methylation-dependent micronutrients in breast tumorigenesis is gaining wider acceptance. However, the association of serum inflammation biomarkers and micronutrient status with expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor-2 (HER-2) by the tumor has not been investigated in Nigerian breast cancer patients. The objective of this study was to determine the levels of serum biomarkers of inflammation [Homocysteine, Nitric Oxide (NO), Hydrogen peroxide (H2O2), Myeloperoxidase (MPO), Tumor necrosis factor alpha (TNF-α), Interleukins 6 and 8 (IL-6 and IL-8)] and DNA methylation-dependent micronutrients [Zinc (Zn), Folic acid, Vitamin B6 and B12] in breast cancer patients with different hormone receptors (ER, PR and HER-2).


Methods: One hundred and fifteen women (80 with breast cancer and 35 controls) were randomly recruited for this study. Serum levels of homocysteine, folic acid, vitamins B6, vitamin B12, TNF-α, IL-6 and IL-8) were analyzed using ELISA, while the levels of NO, MPO, H2O2 and Zn were determined using spectrophotometer in patients with breast cancer and control subjects without breast cancer as well as breast cancer patients with ER, PR and HER-2 expression were determined.


Results: The results showed that mean serum levels of IL-6 (p=0.002), IL-8 (p=0.018) and H2O2 (p=0.000) were significantly increased while TNF-α (p=0.014) and NO levels (p=0.044) were significantly decreased in breast cancer patients compared to healthy controls. However, there were no statistically significant differences in the levels of Zn, homocysteine, Vitamin B6, Vitamin B12 and MPO in breast cancer patients and controls. Furthermore, the levels of serum inflammatory biomarkers and methylation-dependent micronutrients were similar in breast cancer patients with HER-2, ER and PR expression.


Conclusion: Systemic inflammation exists in breast cancer patients but the inflammation biomarkers and methylation-dependent micronutrients did not differ among breast cancer patients with PR, ER and HER-2 expression.

References

1. Lan T, Wang L, Xu Q, Liu W, Jin H, Mao W, et al. Growth inhibitory effect of Cucurbitacin E on breast cancer cells. Int J Clin Exp Pathol. 2013;6(9):1799.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
3. Xuan C, Shamonki J, Chung A, Dinome M, Chung M, Sieling P, et al. Microbial dysbiosis is associated with human breast cancer. PLoS One. 2014;9(1).
4. Cuzick J, Otto F, Baron J, Brown P, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501–7.
5. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control. 2006;17(7):871–88.
6. Arinola O, Charles-Davies M. Micronutrient levels in the plasma of Nigerian females with breast cancer. African J Biotechnol. 2010;7(11):1620–3.
7. Marzo AM De, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256.
8. Elkahwaji JE. The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. Res Reports Urol. 2013;5(1):1.
9. Zhang S, Willett W, Selhub J, Hunter D, Giovannucci E, Holmes M, et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst. 2003;95(5):373–80.
10. Finkelstein J. Methionine metabolism in mammals. J Nutr Biochem. 1990;1(5):228–37.
11. Sun C, Haven T, Wu T, Tsao K, Wu J. Serum total homocysteine increases with the rapid proliferation rate of tumor cells and decline upon cell death: a potential new tumor marker. Clin Chim Acta. 2002;321(1–2):55–62.
12. Wu L, Wu J. Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin Chim Acta. 2002;322(1–2):21–8.
13. Hogg N. The effect of cyst(e)ine on the auto-oxidation of homocysteine. Free Radic Biol Med. 1999;27(1–2):28–33.
14. Stipanuk M. Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Annu Rev Nutr. 2004;24:539–77.
15. Chou Y, Lee M, Wu M, Shih H, Yang T, Yu C, et al. Plasma homocysteine as a metabolic risk factor for breast cancer: findings from a case-control study in Taiwan. Breast Cancer Res Treat. 2007;101(2):199–205.
16. Mason JB, Levesque T. Folate: effects on carcinogenesis and the potential for cancer chemoprevention. Oncology (Williston Park). 1996;10(11):1727-1736,1742-1744.
17. Ames B. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res. 2001 Apr 18;475(1–2):7–20.
18. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr. 2002;132(8 Suppl).
19. Larsson S, Giovannucci E, Wolk A. Folate and risk of breast cancer: a meta-analysis. J Natl Cancer Inst. 2007;99(1):64–76.
20. Lin J, Lee I, Cook N, Selhub J, Manson J, Buring J, et al. Plasma folate, vitamin B-6, vitamin B-12, and risk of breast cancer in women. Am J Clin Nutr. 2008;87(3):734–43.
21. Wei E, Giovannucci E, Selhub J, Fuchs C, Hankinson S, Ma J. Plasma vitamin B6 and the risk of colorectal cancer and adenoma in women. J Natl Cancer Inst. 2005;97(9):684–92.
22. Brieger A, Rink L, Haase H. Differential Regulation of TLR-Dependent MyD88 and TRIF Signaling Pathways by Free Zinc Ions. J Immunol. 2013;191(4):1808–17.
23. Summersgill H, England H, Lopez-Castejon G, Lawrence C, Luheshi N, Pahle J, et al. Zinc depletion regulates the processing and secretion of IL-1β. Cell Death Dis. 2014;5(1).
24. Mayer L, Uciechowski P, Meyer S, Schwerdtle T, Rink L, Haase H. Differential impact of zinc deficiency on phagocytosis, oxidative burst, and production of pro-inflammatory cytokines by human monocytes. Metallomics. 2014;6(7):1288–95.
25. Gupta S, Shukla V, Vaidya M, Roy S, Gupta S. Serum trace elements and Cu/Zn ratio in breast cancer patients. J Surg Oncol. 1991;46(3):178–81.
26. Adzersen K, Jess P, Freivogel K, Gerhard I, Bastert G. Raw and cooked vegetables, fruits, selected micronutrients, and breast cancer risk: a case-control study in Germany. Nutr Cancer. 2003;46(2):131–7.
27. Garland M, Morris J, Colditz G, Stampfer M, Spate V, Baskett C, et al. Toenail trace element levels and breast cancer: a prospective study. Am J Epidemiol. 1996;144(7):653–60.
28. Cui Y, Vogt S, Olson N, Glass A, Rohan T. Levels of zinc, selenium, calcium, and iron in benign breast tissue and risk of subsequent breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1682–5.
29. Piccinini L, Borella P, Bargellini A, Medici C, Zoboli A. A case-control study on selenium, zinc, and copper in plasma and hair of subjects affected by breast and lung cancer. Biol Trace Elem Res. 1996;51(1):23–30.
30. Hammond M, Hayes D, Wolff A, Mangu P, Temin S. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6(4):195–7.
31. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790–800.
32. Kumar V, Abbas AK, Aster JC, Cotran RS. Robbins and Cotran Pathologic Basis of Disease. 2010. 1391 p.
33. Bingle L, Brown N, Lewis C. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196(3):254–65.
34. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953–64.
35. Mosser D. The many faces of macrophage activation. J Leukoc Biol. 2003;73(2):209–12.
36. Verreck F, de Boer T, Langenberg D, Hoeve M, Kramer M, Vaisberg E, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A. 2004;101(13):4560–5.
37. Ahmed HH, Metwally FM, Mahdy E-SM, Shosha WG, Ramadan SS. Clinical value of serum hepatocyte growth factor, B-cell lymphoma-2 and nitric oxide in primary breast cancer patients. Eur Rev Med Pharmacol Sci. 2012;16(7):958–65.
38. Arinola GO, Akinwande K. Cytokine Levels and Micronutrient Status in Ascaris lumbricoides - Infected Nigerian School Children after Albendazole Treatment. Tanzania Med J. 2021;32(2):1–20.
39. Arinola GO, Edem FV. Antioxidant Vitamins Are Correlated with Different Aspects of Phagocytic Processes in Healthy Nigerians: Benefits As Supplements During Antimicrobial Treatment. Sudan J Med Sci. 2020 Sep 30;15(3):225–36.
40. Lin J, Lee I, Song Y, Cook N, Selhub J, Manson J, et al. Plasma homocysteine and cysteine and risk of breast cancer in women. Cancer Res. 2010;70(6):2397–405.
41. Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola M, Nava-Castro K, Castro J, Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 2015;35(1):1–16.
42. Nariţa D, Seclaman E, Ursoniu S, Ilina R, Cireap N,
Anghel A. Expression of CCL18 and interleukin-6 in the plasma of breast cancer patients as compared with benign tumor patients and healthy controls. Rom J Morphol Embryol. 2011;52(4):1261–7.
43. Alokail M, Al-Daghri N, Mohammed A, Vanhoutte P, Alenad A. Increased TNF α, IL-6 and ErbB2 mRNA expression in peripheral blood leukocytes from breast cancer patients. Med Oncol. 2014;31(8):38.
44. Todorović-Raković N, Milovanović J. Interleukin-8 in breast cancer progression. J Interferon Cytokine Res. 2013;33(10):563–70.
45. Katanov C, Lerrer S, Liubomirski Y, Leider-Trejo L, Meshel T, Bar J, et al. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway. Stem Cell Res Ther. 2015;6(1):1-7.
46. Deshmukh SK, Srivastava SK, Bhardwaj A, Singh AP, Tyagi N, Marimuthu S, et al. Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation. Oncotarget. 2015;6(13):11231.
47. Yao C, Lin Y, Chua M, Ye C, Bi J, Li W, et al. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J cancer [Internet]. 2007 Nov 1 [cited 2021 Sep 20];121(9):1949–57.
48. Sheikhpour R. The Role of Interleukin-8 and Its Mechanism in Patients with Breast Cancer: Its Relation with Oxidative Stress and Estrogen Receptor. Int J Cancer Manag. 2017;10(9): e8791.
49. Derin D, Soydinc H, Guney N, Tas F, Camlica H, Duranyildiz D, et al. Serum IL-8 and IL-12 levels in breast cancer. Med Oncol. 2007;24(2):163–8.
50. Olopade C, Frank E, Bartlett E, Alexander D, Dutta A, Ibigbami T, et al. Effect of a clean stove intervention on inflammatory biomarkers in pregnant women in Ibadan, Nigeria: A randomized controlled study. Environ Int. 2017;98:181–90.
51. Nita M, Grzybowski A. The Role of the Reactive Oxygen Species and Oxidative Stress in the Pathomechanism of the Age-Related Ocular Diseases and Other Pathologies of the Anterior and Posterior Eye Segments in Adults. Oxid Med Cell Longev. 2016;2016.
52. Tang C-H, Wei W, Liu L. Regulation of DNA Repair by S-Nitrosylation. Biochim Biophys Acta. 2012;1820(6):730.
53. Izumi T, Wiederhold LR, Roy G, Roy R, Jaiswal A, Bhakat KK, et al. Mammalian DNA base excision repair proteins: Their interactions and role in repair of oxidative DNA damage. Toxicology. 2003;193(1–2):43–65.
54. Zhou X, Fan W, Yang G, Yu M. The clinical significance of PR, ER, NF- κ B, and TNF- α in breast cancer. Dis Markers. 2014;2014.
55. Bhatia A, Sekhon HK, Kaur G. Sex Hormones and Immune Dimorphism. Sci World J. 2014;2014.
56. Al-Saleh K, Salah T, Arafah M, Husain S, Al-Rikabi A, El-Aziz NA. Prognostic significance of estrogen, progesterone and HER2 receptors’ status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia. PLoS One. 2021; 16(3):e0247802.
57. Parise C, Bauer K, Brown M, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009;15(6):593–602.
58. Onitilo A, Engel J, Greenlee R, Mukesh B. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1–2):4–13.
59. Sinha S, Nath J, Mukherjee A, Chatterjee T. Predictive and Prognostic Factors in Breast Cancer and their Association with ER PR HER2/neu Expression. J Carcinog Mutagen. 2016;7(2):1–4.

Article Statistics :Views : 61 | Downloads : 5 : 1